Purchase this article with an account.
WC Stewart, AG P Konstas, VP Kozobolis, I Tersis, JN Leech; The Efficacy and Safety of the Timolol/dorzolamide Fixed Combination Versus Latanoprost in Exfoliation Glaucoma . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3416.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: To evaluate the morning intraocular pressure in patients with exfoliation glaucoma treated with the timolol/dorzolamide fixed combination given twice daily or latanoprost 0.005% given every evening. Methods: We randomized in a masked fashion 65 newly diagnosed exfoliation glaucoma patients to either the timolol/dorzolamide or latanoprost treatment for six weeks and then crossed these over to the other treatment. Results: This study showed that 54 completed patients at 10:00 (peak timepoint), from a baseline intraocular pressure of 31.6 6.5 mm Hg, latanoprost reduced the pressure to 18.9 4.0 mm Hg and the fixed combination to 18.1 3.0 mm Hg (P = 0.052) following two months of chronic dosing. Six patients were discontinued early from both treatment periods due to inadequate intraocular pressure control and two others were discontinued from latanoprost treatment only. The fixed combination showed a greater incidence of taste perversion and stinging upon instillation while latanoprost showed an increased incidence of conjunctival injection (P < 0.05). However, five patients demonstrated either bradycardia or asthmatic symptoms with initiation of the fixed combination therapy. One patient on latanoprost complained of dizziness. Conclusion: This study suggests that both latanoprost and the timolol/dorzolamide fixed combination are efficacious in the treatment of exfoliation glaucoma in reducing the intraocular pressure.
This PDF is available to Subscribers Only